Neisseria Vaccines 2007

References

• Villullas S, Hill DJ, Sessions RB, Rea J, Virji M. Mutational analysis of human CEACAM1: the potential of receptor polymorphism in increasing host susceptibility to bacterial infection. Cell Micro.9(2), 329–346 (2007).
   PubMed Web of Science ®Google Scholar
• Johansson L, Rytkönen A, Bergman P et al. CD46 in meningococcal disease. Science301, 373–375 (2003).
   PubMed Web of Science ®Google Scholar
• González S, Caballero E, Soria Y, Cobas K, Granadillo M, Pajón R. Immunization with Neisseria meningitidis outer membrane vesicles prevents bacteremia in neonatal mice. Vaccine24(10), 1633–1643 (2006).
   PubMedGoogle Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus: I. The role of humoral antibodies. J. Exp. Med.129, 1307–1326 (1969).
   PubMed Web of Science ®Google Scholar
• Trotter C, Findlow J, Balmer P et al. Seroprevalence of bactericidal and anti-outer membrane vesicle antibody to Neisseria meningitidis group B in England. Clin. Vaccine Immunol.14(7), 863-8 (2007).
   PubMedGoogle Scholar
• Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet357, 195–196 (2001).
   PubMed Web of Science ®Google Scholar
• Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet364, 365–367 (2004).
   PubMed Web of Science ®Google Scholar
• Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann.14, 67–80 (1991).
   PubMedGoogle Scholar
• Sierra GVC, Campa HC, Varcarel NM et al. Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann.14, 195–210 (1991).
   PubMedGoogle Scholar
• Boslego J, Garcia J, Cruz C et al; the Chilean National Committee for Meningococcal Disease. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine13, 821–829 (1995).
   PubMed Web of Science ®Google Scholar
• Holst J, Feiring B, Fuglesang JE et al. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine21, 734–737 (2003).
   PubMed Web of Science ®Google Scholar
• Rodríguez AP, Dickinson F, Baly A, Martinez R. The epidemiological impact of antimeningococcal B vaccination in Cuba. Mem. Inst. Oswaldo Cruz94, 433–440 (1999).
   PubMed Web of Science ®Google Scholar
• de Moraes JC, Perkins BA, Camargo MC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet340, 1074–1078 (1992).
   PubMed Web of Science ®Google Scholar
• Milagres LG, Ramos SR, Sacchi CT et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect. Immun.62, 4419–4424 (1994).
   PubMed Web of Science ®Google Scholar
• Milagres LG, Gorla MC, Rebelo MC, Barroso DE. Bactericidal antibody responses to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunisation with an outer membrane protein vaccine. FEMS Immunol. Med. Microbiol.28, 319–327 (2000).
   PubMedGoogle Scholar
• Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomised controlled trial in Chile. JAMA281, 1520–1527 (1999).
   PubMed Web of Science ®Google Scholar
• Wedege E, Høiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect. Immun.66, 3223–3231 (1998).
   PubMed Web of Science ®Google Scholar
• Boutriau D, Poolman J, Borrow R et al. Immunogenicity and safety of three doses of a bivalent (B:4:P1.19,15 and B:4:P1.7–2,4) meningococcal outer membrane vesicle vaccine in healthy adolescents. Clin. Vac. Immunol.14, 65–73 (2007).
   Google Scholar
• Wedege E, Bolstad K, Aase A et al. Functional and specific antibody responses in adult volunteers vaccinated with two different meningococcal serogroup B outer membrane vesicle vaccines in New Zealand. Clin. Vaccine Immunol.14(7) 863-868 (2007).
   PubMedGoogle Scholar
• van den Dobbelsteen G, van Dijken H, Hamstra H, Ummels R, van Alphen L, van der Ley P. From HexaMen to NonaMen: expanding a multivalent PorA-based meningococcal outer membrane vesicle vaccine. Presented at: 14th International Pathogenic Neisseria Conference, WI, USA, (Abstr. P153) (2004).
   Google Scholar
• Yero CD, Pajón FR, Caballero ME et al. Immunization of mice with Neisseria meningitidis serogroup B genomic expression libraries elicits functional antibodies and reduces the level of bacteraemia in an infant rat model. Vaccine23(7), 932–939 (2005).
   PubMed Web of Science ®Google Scholar
• Betancourt L, Gil J, Besada V et al. SCAPE: a new tool for the selective capture of peptides in protein identification. J. Proteome Res.4(2), 491–496 (2005).
   PubMed Web of Science ®Google Scholar
• Sánchez A, González LJ, Ramos Y et al. Selective isolation of lysine-free tryptic peptides delimited by arginine residues: a new tool for proteome analysis. J. Proteome Res.5(5), 1204–1213 (2006).
   PubMedGoogle Scholar
• Sánchez A, González LJ, Betancourt L et al. Selective isolation of multiple positively charged peptides for 2-DE-free quantitative proteomics. Proteomics6(16), 4444–4455 (2006).
   PubMedGoogle Scholar